PSMA-1-SMCC
PSMA-1-SMCC is a selective binding agent targeting Prostate-Specific Membrane Antigen (PSMA) . PSMA-1-SMCC is promising for research of targeted imaging for prostate cancer[1][2].
Product Specifications
UNSPSC
12352209
Target
PSMA
Related Pathways
Immunology/Inflammation
Field of Research
Cancer
Purity
98.16
Smiles
O=C(N[C@H](CCC(O)=O)C(N[C@H](CCC(O)=O)C(N[C@H](CCC(O)=O)C(N[C@@H](CCCCNC(C1CCC(CN2C(C=CC2=O)=O)CC1)=O)C(N)=O)=O)=O)=O)CCCCCNC([C@@H]3CC[C@@H](CNC(CC[C@@H](C(O)=O)NC(N[C@@H](CCC(O)=O)C(O)=O)=O)=O)CC3)=O
Molecular Formula
C58H87N11O23
Molecular Weight
1306.37
References & Citations
[1]Wang X, et al. Theranostic Agents for Photodynamic Therapy of Prostate Cancer by Targeting Prostate-Specific Membrane Antigen. Mol Cancer Ther. 2016 Aug;15 (8) :1834-44.|[2]Sammouda R. Prostate cancer diagnosis based on the segmentation and analysis of NIR images obtained using two PSMA-1 based PDT conjugates PSMA-1-Pc413 and PSMA-1-IR700[J]. International Journal of Sciences: Basic and Applied Research, 2016, 25 (2) : 218-232.
Shipping Conditions
Blue Ice
Storage Conditions
-80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture)
Scientific Category
Peptides
Clinical Information
No Development Reported
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNC471063-100 1x 100 µL
VEGF-A (VEGF/1063), CF647 conjugate, 0.1mg/mL
Sign In for Pricing
View Details